EGF Theramed Health (TSE:TMED)

:TMED

TMED

EGF Theramed Health

RESEARCH TOOLSreports

EGF Theramed Health (TMED) Price & Analysis

6 Followers

TMED Stock Chart & Stats

C$0.07

C$0.00(0.00%)

At close: Dec 30 4:00 PM EST

C$0.07

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.06 - C$0.13

Previous CloseN/A

Volume0.00

Average Volume (3M)1.23K

Market Cap

C$929.33K

Enterprise ValueC$2.54M

Total Cash (Recent Filing)C$10.47K

Total Debt (Recent Filing)C$1.63M

Price to Earnings (P/E)―

Beta0.18

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding11,616,665

10 Day Avg. Volume1,800

30 Day Avg. Volume1,233

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.26

Price to Sales (P/S)0.00

P/FCF Ratio38.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Near-term Cash GenerationThe shift to slightly positive operating and free cash flow in 2025 indicates the company can, at least temporarily, generate cash from operations. Over a 2-6 month horizon, even modest positive cash flow can reduce immediate liquidity strain, extend runway, and allow management to focus on operational adjustments rather than urgent financing.

Reduction In Historical LossesThe multi-year improvement from the extreme 2020 loss toward smaller recurring losses through 2021–2024 reflects structural progress in cost control or scaling back high-burn activities. This durable trend suggests management has taken steps to moderate operating losses, which supports a path to stabilization over several quarters if maintained.

Evidence Of Operating DisciplineThe documented improvement in operating cash flow implies operational adjustments or reduced cash burn that are sustainable over the medium term if continued. Demonstrable discipline in converting losses into positive cash flow, even modestly, strengthens short-term solvency and gives management more time to execute strategic fixes without immediate capital raises.

Bears Say

Negative Shareholder EquityNegative equity is a structural solvency concern: liabilities exceed assets, constraining borrowing capacity and limiting strategic flexibility. Over the medium term this raises risk of creditor actions, forced recapitalization, or dilution, and it materially weakens the company’s ability to fund operations without external financing.

No Reported RevenueAbsent any recorded revenue across the reporting history, the company lacks a validated commercial model and recurring cash inflows. This structural deficiency forces reliance on financing or asset sales for operating needs and makes sustainable margin improvement or scale unlikely without a clear, demonstrable revenue initiative.

Debt With Tiny Asset BaseMeaningful debt paired with a negligible asset base implies weak collateral and high refinancing risk. Structurally, this elevates the likelihood of distress or dilution if cash generation falters, as creditors may demand repayment or more restrictive covenants, limiting the firm’s ability to invest or react to market needs.

EGF Theramed Health News

EGF Theramed refreshes board and finance leadership

EGF Theramed Health ( ($TSE:TMED) ) has shared an announcement. EGF Theramed Health Corp. has appointed Lin Ye...

1M ago

TMED FAQ

What was EGF Theramed Health’s price range in the past 12 months?

EGF Theramed Health lowest stock price was C$0.06 and its highest was C$0.13 in the past 12 months.

What is EGF Theramed Health’s market cap?

EGF Theramed Health’s market cap is C$929.33K.

When is EGF Theramed Health’s upcoming earnings report date?

EGF Theramed Health’s upcoming earnings report date is Jun 02, 2026 which is in 53 days.

How were EGF Theramed Health’s earnings last quarter?

EGF Theramed Health released its earnings results on Feb 24, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.006.

Is EGF Theramed Health overvalued?

According to Wall Street analysts EGF Theramed Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does EGF Theramed Health pay dividends?

EGF Theramed Health does not currently pay dividends.

What is EGF Theramed Health’s EPS estimate?

EGF Theramed Health’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does EGF Theramed Health have?

EGF Theramed Health has 11,616,665 shares outstanding.

What happened to EGF Theramed Health’s price movement after its last earnings report?

EGF Theramed Health reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of EGF Theramed Health?

Currently, no hedge funds are holding shares in TSE:TMED

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

EGF Theramed Health

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.